Current nonclinical approaches for immune assessments of immuno-oncology biotherapeutics
Christine Grimaldi(Boehringer Ingelheim (United States)), Diann Blanset(Boehringer Ingelheim (France)), Meredith A. Steeves(Eli Lilly (United States)), Alex Ibraghimov(AbbVie (United States)), Wendy Freebern(Bristol-Myers Squibb (Germany)), Frank R. Brennan(AstraZeneca (United Kingdom)), Changhua Ji(Yale University), Sherri Dudal(Roche (Switzerland)), Andrea Kießling(Novartis (Switzerland)), Franziska Regenass-Lechner(Roche (Switzerland)), Marie-Soleil Piché(Charles River Laboratories (United States)), Jacintha Shenton(Janssen (Belgium)), Rodney A. Prell, Benno Rattel(Amgen (Germany)), Claudette L. Fuller(United States Army Medical Research Institute of Infectious Diseases), Karen Price(Purchase College), Sven Kronenberg(Roche (Switzerland))
Cited by 7
Related Papers
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Cancer Drug Discovery and Development
|Humana Press eBooks|2003|194
Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival
|The Journal of Immunology|2005|183
Reduction in Transforming Growth Factor β Receptor I Expression and Transcription Factor CBFa1 on Bone Cells by Glucocorticoid
|Journal of Biological Chemistry|1998|158
Activation of Triggering Receptor Expressed on Myeloid Cells-1 on Human Neutrophils by Marburg and Ebola Viruses
|Journal of Virology|2006|110